Last updated: October 27, 2026
Amevive, the brand name for alefacept, was an early biologic treatment for moderate-to-severe chronic plaque psoriasis. FDA approval in 2003 gave Biogen a first-mover position in the U.S. psoriasis biologics market, but the product had limited commercial durability. Weekly intramuscular dosing, CD4-cell monitoring, modest efficacy relative to later biologics, restricted retreatment practices, and a slow infusion-center-oriented treatment model reduced its competitiveness. Astellas discontinued U.S. commercialization in 2011 for business reasons. Amevive has no current U.S. commercial market, no meaningful generic-substitution pathway, and no identified biosimilar competition.
What is Amevive and how did alefacept work?
Amevive is a recombinant dimeric fusion protein containing the extracellular CD2-binding domain of human LFA-3 linked to the Fc portion of human IgG1. Alefacept inhibits T-cell activation and reduces circulating memory T cells, including CD45RO-positive T cells involved in psoriasis pathophysiology.
The FDA-approved regimen was 15 mg administered intramuscularly once weekly for 12 weeks. Patients required CD4 lymphocyte monitoring before and during therapy. The product was approved for adults with moderate-to-severe chronic plaque psoriasis who were candidates for systemic therapy or phototherapy [1].
FDA product profile
| Attribute |
Amevive |
| Active ingredient |
Alefacept |
| Molecular type |
LFA-3/IgG1 fusion protein |
| Original sponsor |
Biogen |
| Later commercial rights holder |
Astellas |
| FDA approval |
2003 |
| Indication |
Moderate-to-severe chronic plaque psoriasis |
| Initial dosing |
15 mg intramuscularly weekly for 12 weeks |
| Administration |
Intramuscular injection |
| Monitoring |
CD4 lymphocyte counts |
| Current U.S. status |
Commercially discontinued |
| Generic pathway |
Not available through ANDA |
| Biosimilar status |
No established commercial biosimilar market |
When did Amevive lose exclusivity and when was it discontinued?
Amevive’s practical commercial exclusivity ended before the product’s formal discontinuation. FDA approval occurred in 2003, but later biologic competition and product-specific limitations eroded demand well before Astellas withdrew the product.
Astellas discontinued Amevive in the United States in 2011. Public communications described the decision as a business decision rather than a safety recall or FDA-required withdrawal [2]. The product’s commercial life was therefore approximately eight years after approval.
Amevive exclusivity timeline
| Year |
Event |
| 2001 |
Phase III alefacept psoriasis data published |
| 2003 |
FDA approved Amevive |
| 2006 |
Astellas obtained commercial rights from Biogen for Amevive in relevant markets |
| 2008-2010 |
Competition expanded from TNF inhibitors and phototherapy alternatives |
| 2011 |
Astellas discontinued U.S. commercialization |
| After 2011 |
No active U.S. commercial market |
The key commercial issue was not a single patent expiration date. Amevive was a biologic licensed under the pre-BPCIA regulatory framework, and its market position weakened as competing biologics improved efficacy, dosing convenience, and payer acceptance.
What was Amevive’s financial trajectory?
Amevive did not become a major revenue contributor for Biogen or Astellas. Public company reporting did not consistently disclose Amevive sales as a separate material product line. Reported revenue was generally aggregated into broader product or therapeutic-area categories, preventing a reliable public year-by-year Amevive sales series.
The available financial record supports a decline-and-withdrawal pattern rather than a growth trajectory:
- Biogen launched Amevive into an emerging psoriasis biologics market.
- Astellas later assumed commercial responsibility.
- Product differentiation weakened as newer therapies delivered higher skin-clearance rates and more convenient dosing.
- Amevive was discontinued rather than developed into a durable franchise.
Why revenue did not scale
Amevive faced several structural revenue constraints:
- The approved course consisted of 12 weekly injections, limiting recurring revenue unless patients were retreated.
- CD4 monitoring increased clinical-management requirements.
- The label included restrictions and precautions related to immunosuppression and infection risk.
- Clinical efficacy was weaker than later interleukin-17 and interleukin-23 therapies.
- The treatment was not positioned as a convenient self-administered maintenance product.
- Physicians had more commercially attractive alternatives as psoriasis biologics matured.
The product’s early entry created regulatory value, but early entry did not translate into durable market share. Product-level revenue figures should not be inferred from the size of the psoriasis biologics market because Amevive sales were not separately reported in a consistent public series.
How did Amevive compare with competing psoriasis biologics?
Amevive entered a market with fewer biologic options than exist today. Its initial competitors included TNF inhibitors such as Enbrel and Remicade. Later competition included Humira, Stelara, Cosentyx, Taltz, Tremfya, Ilumya, and Skyrizi.
Commercial comparison
| Product |
Mechanism |
Market entry period |
Typical strategic advantage over Amevive |
| Amevive |
LFA-3/IgG1 T-cell modulator |
2003 |
Early biologic option |
| Enbrel |
TNF inhibitor |
Earlier than Amevive |
Established physician familiarity and broader use |
| Humira |
TNF inhibitor |
2000s |
Subcutaneous self-administration and broad indications |
| Stelara |
IL-12/23 inhibitor |
2009 |
Less frequent dosing and stronger efficacy profile |
| Cosentyx |
IL-17 inhibitor |
2015 |
High skin-clearance efficacy |
| Taltz |
IL-17 inhibitor |
2016 |
High PASI response rates |
| Tremfya |
IL-23 inhibitor |
2017 |
Durable efficacy and infrequent dosing |
| Skyrizi |
IL-23 inhibitor |
2019 |
High efficacy and quarterly maintenance dosing |
Early studies reported PASI 75 response rates for alefacept that were materially below the rates later achieved by IL-17 and IL-23 inhibitors. In pivotal alefacept trials, approximately 21% of patients receiving the approved 15 mg regimen achieved PASI 75 after the treatment course, compared with approximately 5% receiving placebo [3].
That efficacy profile could support a niche product in 2003. It became commercially weak once treatment decisions shifted toward rapid and near-complete skin clearance.
What was the clinical and regulatory weakness of Amevive?
Amevive’s clinical profile imposed costs on prescribers, patients, and payers.
Efficacy
Amevive’s response rate was modest by current psoriasis standards. Patients often required additional treatment after the 12-week course. The product did not offer the sustained, high-clearance profile associated with later IL-17 and IL-23 inhibitors.
Administration
The regimen required weekly intramuscular administration for 12 weeks. That was less convenient than oral therapy or newer self-injected biologics with two-week, four-week, eight-week, or longer maintenance intervals.
Monitoring
Amevive required CD4 monitoring. Patients with low CD4 counts were at increased risk from additional immune suppression, and the label required clinicians to monitor lymphocyte levels. Monitoring added operational friction and could discourage use when alternatives did not require comparable laboratory oversight [1].
Safety and positioning
Amevive’s mechanism reduced T-cell populations, creating a clinical need to monitor infection and malignancy-related risks. Even where the absolute risk was acceptable, the perception of broader immune effects reduced its attractiveness relative to more targeted therapies.
What patents protected Amevive?
Amevive was protected primarily through biologic, fusion-protein, formulation, manufacturing, and platform patent rights rather than through a conventional small-molecule Orange Book patent strategy.
The Orange Book is designed primarily for approved drug products submitted through the NDA framework. Amevive was approved as a biologic license application product. As a result, a conventional Orange Book patent listing does not provide a complete account of its historical patent estate.
Patent and regulatory position
| Issue |
Amevive position |
| Orange Book listing |
Not a reliable source for the full alefacept patent estate |
| ANDA generic pathway |
Not applicable |
| 351(k) biosimilar pathway |
Legally available in principle for comparable biologics |
| Current marketed reference product |
No active U.S. commercial product |
| Patent litigation affecting current launch |
No material current launch dispute identified |
| Patent value today |
Primarily historical or platform-related |
The relevant historical rights would have included claims directed to LFA-3 immunoglobulin fusion proteins, nucleic acids, host cells, expression systems, purification processes, and therapeutic use in immune-mediated diseases. The commercial value of those rights declined sharply after product withdrawal.
Because Amevive was discontinued in 2011, any residual patent rights would not by themselves create a meaningful commercial barrier unless a successor product, licensed technology, or new alefacept formulation entered development.
Does Amevive have biosimilar or generic competition?
Amevive does not have ordinary generic competition. Alefacept is a complex biologic protein, so an ANDA-based generic substitution pathway does not apply.
A biosimilar could theoretically be developed under section 351(k) of the Public Health Service Act. In practice, the absence of a currently marketed U.S. reference product creates a serious commercial problem. A sponsor would face:
- No active U.S. sales base to capture.
- Limited physician demand for an obsolete mechanism.
- Competition from higher-efficacy biologics.
- Manufacturing complexity associated with a fusion protein.
- Limited payer incentive to adopt an older product.
- Uncertain interchangeability and substitution economics.
The FDA’s Purple Book framework is more relevant than the Orange Book for biologic exclusivity and biosimilar status. Amevive’s 2003 approval predates the modern biosimilar market, and its withdrawal eliminates the commercial rationale for a conventional biosimilar launch [4].
Which companies challenged Amevive commercially?
No major company needed to challenge Amevive through a Paragraph IV filing. Paragraph IV certifications apply to ANDA applicants challenging listed patents associated with an NDA. Amevive was not exposed to that standard generic litigation pathway.
The competitive challenge came from marketed therapies:
- Amgen and Wyeth with Enbrel.
- Johnson & Johnson and Janssen with Remicade and later Stelara.
- AbbVie with Humira.
- Novartis with Cosentyx.
- Eli Lilly with Taltz.
- Janssen with Tremfya.
- Sun Pharma with Ilumya.
- AbbVie with Skyrizi.
These products displaced Amevive through clinical differentiation, dosing convenience, broader indications, and commercial investment rather than through a patent-centered generic attack.
What licensing deals affected Amevive?
Biogen originated and developed alefacept. Astellas later obtained commercial rights and assumed responsibility for marketing the product in relevant territories. Publicly available company disclosures do not provide a detailed product-level economic breakdown of royalties, milestone payments, or net sales transfers.
The commercial-rights transaction was strategically rational at the time. Astellas had a larger commercial infrastructure and an expanding immunology portfolio. The transaction did not resolve Amevive’s underlying market limitations. A rights transfer can improve promotion and distribution, but it cannot compensate for weak relative efficacy, monitoring burdens, or an aging treatment profile.
What was the litigation and settlement status for Amevive?
No material current patent litigation or settlement agreement is associated with Amevive’s U.S. commercial status. The product’s withdrawal was a business decision, not the result of a publicly identified Paragraph IV settlement or a court-ordered market exit.
There is also no meaningful current launch scenario involving a generic or biosimilar entrant. The absence of a marketed reference product, combined with the competitive strength of newer psoriasis biologics, makes a re-entry or follow-on launch commercially unlikely.
How strong is the Amevive patent estate today?
The historical patent estate may have been technically meaningful, but its current commercial strength is low.
Patent strength depends on three factors:
- Remaining enforceable term.
- Scope of claims covering the approved product or a viable follow-on.
- Economic value of the protected product after market withdrawal.
Amevive performs poorly on the third factor. Even a surviving process or formulation patent would have limited value without a commercially attractive alefacept product. The strongest remaining barriers would likely concern manufacturing know-how, cell-line development, protein expression, analytical characterization, and regulatory comparability rather than a conventional composition-of-matter monopoly.
What generic launch risks exist for Amevive?
The principal risk is not generic erosion. It is asset obsolescence.
A potential successor would encounter four launch barriers:
| Barrier |
Commercial effect |
| No active U.S. reference-product franchise |
Limits substitution economics |
| Inferior efficacy versus newer biologics |
Weakens prescriber demand |
| Weekly treatment-course structure |
Reduces convenience |
| Manufacturing complexity |
Raises development cost and regulatory risk |
A sponsor could theoretically reposition alefacept for a niche immune-mediated indication, but that would require new clinical development, a new commercial strategy, and a regulatory pathway independent of the discontinued psoriasis franchise.
What is Amevive’s geographic market status?
Amevive’s most important market was the United States. The U.S. withdrawal effectively ended its principal commercial significance. Historical availability outside the United States was more limited and depended on local approvals, reimbursement, and commercial arrangements.
There is no current global growth thesis for Amevive. Any remaining geographic rights would have low value unless tied to a new indication, a reformulated product, or a licensing arrangement based on alefacept’s underlying technology.
Key Takeaways
- Amevive, or alefacept, was FDA-approved in 2003 for moderate-to-severe plaque psoriasis.
- Astellas discontinued U.S. commercialization in 2011 for business reasons.
- Product-level revenue was not disclosed consistently, but the commercial trajectory was one of limited uptake followed by withdrawal.
- Weekly intramuscular dosing, CD4 monitoring, modest efficacy, and limited retreatment economics weakened the product.
- Later IL-17 and IL-23 biologics made Amevive clinically and commercially obsolete.
- Amevive was not subject to a conventional ANDA Paragraph IV challenge.
- No meaningful current generic or biosimilar market exists.
- The Orange Book does not provide a complete historical account of Amevive’s biologic patent estate.
- Residual patent or manufacturing rights have limited standalone value without a commercially viable alefacept product.
- The asset’s financial value is primarily historical unless a new indication or successor formulation is developed.
FAQs about Amevive and alefacept
Is Amevive still available in the United States?
No. Astellas discontinued U.S. commercialization in 2011.
Was Amevive a biologic or a conventional drug?
Amevive was a biologic fusion protein approved through a biologics license application.
Can a generic company make a generic version of Amevive?
Not through the standard ANDA pathway. A comparable product would need to follow a biologic development pathway, such as a biosimilar application, and would face limited commercial demand.
Did Amevive lose exclusivity because of a Paragraph IV patent challenge?
No material Paragraph IV challenge is associated with its withdrawal. The product lost commercial relevance through competition and was later discontinued for business reasons.
Could alefacept return as a psoriasis treatment?
A return would require a new commercial strategy and likely additional regulatory or clinical work. The product would face strong competition from biologics with higher efficacy and more convenient dosing.
References
- U.S. Food and Drug Administration. (2009). Amevive (alefacept) prescribing information. https://www.accessdata.fda.gov
- Astellas Pharma Inc. (2011). Amevive U.S. commercial discontinuation communication. Astellas corporate communications archive. https://www.astellas.com
- Ellis, C. N., Krueger, G. G., & Alefacept Clinical Study Group. (2001). Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. New England Journal of Medicine, 345(4), 248-255. https://doi.org/10.1056/NEJMoa011007
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
- National Institute for Health and Care Excellence. (2006). Etanercept and efalizumab for the treatment of adults with psoriasis. Technology appraisal guidance. https://www.nice.org.uk